Shares of Shire PLC (NASDAQ:SHPG) have been assigned an average recommendation of “Hold” from the eighteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $217.89.
SHPG has been the subject of a number of analyst reports. Royal Bank of Canada restated a “buy” rating and set a $213.00 price objective on shares of Shire in a research report on Monday, October 2nd. Stifel Nicolaus restated a “buy” rating and set a $245.00 price objective on shares of Shire in a research report on Sunday, October 8th. FBR & Co assumed coverage on Shire in a research report on Thursday, October 19th. They set a “buy” rating and a $201.00 price target for the company. Zacks Investment Research lowered Shire from a “hold” rating to a “sell” rating in a research report on Friday, October 20th. Finally, ValuEngine upgraded Shire from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th.
A number of hedge funds have recently made changes to their positions in the business. Quadrant Capital Group LLC boosted its position in Shire by 3.7% during the 2nd quarter. Quadrant Capital Group LLC now owns 1,839 shares of the biopharmaceutical company’s stock worth $280,000 after acquiring an additional 66 shares during the period. Bayesian Capital Management LP raised its stake in shares of Shire by 3.9% in the 2nd quarter. Bayesian Capital Management LP now owns 3,947 shares of the biopharmaceutical company’s stock worth $652,000 after buying an additional 147 shares in the last quarter. ETRADE Capital Management LLC raised its stake in shares of Shire by 2.6% in the 2nd quarter. ETRADE Capital Management LLC now owns 6,218 shares of the biopharmaceutical company’s stock worth $1,028,000 after buying an additional 160 shares in the last quarter. L & S Advisors Inc raised its stake in shares of Shire by 6.3% in the 2nd quarter. L & S Advisors Inc now owns 2,886 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 171 shares in the last quarter. Finally, Roberts Glore & Co. Inc. IL raised its stake in shares of Shire by 10.2% in the 2nd quarter. Roberts Glore & Co. Inc. IL now owns 2,218 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 206 shares in the last quarter. Institutional investors own 20.23% of the company’s stock.
Shire (SHPG) traded down $0.86 during trading hours on Monday, reaching $147.55. The company had a trading volume of 1,098,100 shares, compared to its average volume of 1,202,044. Shire has a twelve month low of $137.17 and a twelve month high of $192.15. The firm has a market cap of $44,720.00, a price-to-earnings ratio of 27.79, a P/E/G ratio of 0.79 and a beta of 1.59. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.
Shire (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.64 by $0.17. Shire had a return on equity of 14.41% and a net margin of 10.95%. The business had revenue of $3.70 billion during the quarter. During the same quarter in the prior year, the firm earned $3.17 EPS. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. sell-side analysts forecast that Shire will post 15 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Shire PLC (SHPG) Receives Average Recommendation of “Hold” from Brokerages” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://ledgergazette.com/2018/01/15/shire-plc-shpg-receives-average-recommendation-of-hold-from-brokerages.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.